Trial reportDrug design, development and therapy2026
Isobolographic Analysis of the Interaction Between Remimazolam and Etomidate in General Anesthesia Induction: A Prospective, Sequential Allocation Study Based on the Dixon Up-and-Down Method.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the sedative interaction between the new benzodiazepine derivative remimazolam and etomidate during general anesthesia induction and determine the appropriate dose ratio for their combined use. Patients and Methods: Patients scheduled for general anesthesia, aged 18 to 60 years with a BMI of 18 to 28 kg/m Results: The ED Conclusion: During general anesthesia induction, when the dose ratios of remimazolam to etomidate are approximately 1:1.29 and 1:0.39, the two drugs exert a synergistic sedative effect, with the strongest synergism observed at the dose ratio of 1:1.29.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.